Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAS-IL-1Ra
- Development stage
- Preclinical
- Lead developer
- Pasithea Therapeutics
- Modality
- Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
PAS-IL-1Ra is a long-acting recombinant fusion protein consisting of the human interleukin-1 receptor antagonist (IL-1Ra) and a PASylation tail. Developed by XL-protein GmbH, the drug utilizes the proprietary PASylation technology—a genetic fusion with a conformationally disordered polypeptide sequence composed of Proline, Alanine, and Serine (PAS)—to increase the hydrodynamic volume of the molecule. This modification significantly extends the plasma half-life by reducing renal filtration, addressing the rapid clearance and short half-life characteristic of the native IL-1Ra (anakinra). PAS-IL-1Ra acts as a competitive inhibitor of interleukin-1 (IL-1) by binding to the IL-1 receptor type I (IL-1RI), thereby blocking the pro-inflammatory signaling of both IL-1α and IL-1β. It is primarily investigated for the treatment of chronic inflammatory conditions such as rheumatoid arthritis and gout, where a reduced dosing frequency compared to daily anakinra injections would be therapeutically advantageous.
- Other names
- PASylated IL-1RaPASylated interleukin-1 receptor antagonist
02
Targets
IL1R2 (Interleukin-1 receptor type II)IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on PAS-IL-1Ra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAS-IL-1Ra.